TCR2 (Series B)
Funding Details
Awarder
Inbox
Date Award
March 21, 2018
Vertical
Immuno-oncology
Funding URL
View Funding Page
Funding Amount
$125,000,000
Company Info
Founding Year
2015
Traction
The company will advance its lead solid tumor program TC-210 targeting mesothelin into the clinic in 2018.
Founders
Dr. Patrick Baeuerle
Market
Cancer therapies
Location
Cambridge, MA, USA
Coinvestors
6 Dimensions Capital, Alexandria Real Estate Equities, ArrowMark Partners, Curative Ventures, Haitong International Securities, Hillhouse Capital Group, Lucion Group, Mirae Asset Venture Investment, Redmile Group, Sirona Capital, Syno Capital
Company Description

TCR2 is a discovery stage pharmaceutical company that developed a unique proprietary TRuC™ platform.

Links
WebsiteCrunchbaseLinkedIn
Back to HomeBack to Immuno-oncology DealsView Funding Announcement